11月7日 - ** 医疗设备制造商 Haemonetics 的股价HAE.N上涨 4%，至 69.79 美元。
** 美国银行全球研究将HAE的评级从 "跑输大市 "上调至 "中性"，并将目标价从58美元上调至75美元，较上一交易日收盘价高出11.4%。
** 由于 HAE 的 "审慎 "预测并不依赖血管闭合设备 Vascade 的反弹，而且血浆量也有上升空间，因此 BofA 认为该公司的设置风险较低。
** 注意到港机工程调低了Vascade的复苏预期，意味不需要急剧反弹便能达到指导目标
** 认为血浆量增长有上升空间，上一季度美国血浆量增长恢复到高个位数，欧洲达到两位数。
** 包括本交易日的走势在内，HAE股价今年累计下跌约10%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.